Lantheus Holdings, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LNTH in the last 30 days.
See all $LNTH insider activity →Lantheus Holdings (LNTH) shares dropped 3% after-hours on reports of a $7B acquisition offer from Curium, valued at $102 per share upfront, below its $108.03 closing price. The deal includes $12.50 per share in contingent value rights, totaling $8B. No final agreement has been reached.
Lantheus Holdings (Nasdaq: LNTH) said the FDA approved TAUKLARIFY, a tau PET imaging agent for Alzheimer’s disease diagnostics. The company said the agent is intended to visualize tau pathology to support more precise assessment. The article links the approval to Lantheus’ broader molecular imaging expansion beyond its existing products.
Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
Over the past 7 days, alphai's AI scored 1 news story mentioning LNTH (Lantheus Holdings, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent LNTH coverage spans earnings, mergers & acquisitions and regulation.
Deal offer creates downside pressure; potential upside if premium improves.
FDA approval is a positive commercialization catalyst for LNTH’s Alzheimer’s imaging franchise, but the article flags execution and competitive risks.
FDA approval is a direct commercialization catalyst for TAUKLARIFY and can support near-term sentiment and uptake expectations.
FDA approval is a direct commercialization and reimbursement catalyst for Lantheus’ radiopharmaceutical pipeline, with near-term focus on launch readiness and partner commercialization.
Beat on revenue and adjusted EPS supports near-term sentiment, but the article flags expected revenue and EPS declines over the next 12 months.
alphai scores every news story that mentions LNTH with an AI model for sentiment and relevance, and aggregates insider trades from Lantheus Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lantheus Holdings (LNTH) shares dropped 3% after-hours on reports of a $7B acquisition offer from Curium, valued at $102 per share upfront, below its $108.03 closing price. The deal includes $12.50 per share in contingent value rights, totaling $8B. No final agreement has been reached.
2 min readLantheus Holdings (Nasdaq: LNTH) said the FDA approved TAUKLARIFY, a tau PET imaging agent for Alzheimer’s disease diagnostics. The company said the agent is intended to visualize tau pathology to support more precise assessment. The article links the approval to Lantheus’ broader molecular imaging expansion beyond its existing products.
5 min readBiopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min readLantheus Holdings (NASDAQ: LNTH) said the FDA approved TAUKLARIFY (florquinitau F 18 injection), also known as MK-6240, for tau PET imaging in adults with cognitive impairment being evaluated for Alzheimer’s disease to identify tau NFT pathology. Approval is based on two blinded studies of 500+ subjects and safety in 1,734; common adverse reactions included headache and nausea.
6 min readLantheus Holdings (NASDAQ: LNTH) reported Q2 CY2026 revenue of $388.2 million, up 2.7% year on year, ahead of Wall Street expectations. Non-GAAP adjusted EPS was $1.55, 18.9% above consensus. The article also cites adjusted operating margin of 31% and analyst expectations for revenue to decline 3.2% and full-year EPS to fall from $5.95 to $5.55.
5 min readLantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lantheus Reports Second Quarter 2026 Financial Results • Worldwide revenue of $388.2 million in the second quarter of 2026 • GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 • Adjusted fully diluted earnings per share of
6 min readLantheus Holdings (NASDAQ: LNTH) is set to report Q2 results Thursday before the bell. The article notes it beat prior-quarter revenue expectations with $377.3 million revenue, up 1.2% YoY, but missed full-year revenue guidance expectations. For the upcoming quarter, analysts expect revenue down 4.7% YoY. LNTH shares are down 1.8% over a month; average analyst price target is $107.22 vs $100.97.
3 min readCurium, backed by CapVest Partners, agreed to buy Nasdaq-listed Lantheus in an all-cash deal worth up to about $8bn. Curium will pay $102.50 per share at closing plus non-transferable CVRs up to $12.00 per share, totaling $114.50. The offer includes premiums of 29% to 38% versus recent averages and needs regulatory and shareholder approvals, expected to close in H1 2027.
4 min readLantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement Merger Agreement On August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“ Lantheus ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Curium US
6 min readTD Cowen downgraded Lantheus Holdings (LNTH) to Hold from Buy and cut its price target to $102.50 from $110.00. Analyst Tara Bancroft said the Curium deal is fair and sees >50% odds of most contingent value milestones, but less optimism on the top PSMA PET tier. The stock trades near $102.03. Separately, the FDA issued a Complete Response Letter for LNTH-2501.
4 min read
